We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Cases of the deadly infection have soared among coronavirus patients in India and Nepal
Half of all hospitalised patients in the US are given company’s remdesivir
Gilead’s antiviral drew praise from the White House and a scramble for orders. But does it work?
Gilead drug has ‘no meaningful effect’ on survival or need for ventilation, says health body
Company mounts defence as it reveals treatment generated $873m in third-quarter revenue
US agency grants first regulatory consent for a drug to treat Covid-19 patients
Drugmaker Gilead was briefed on poor results of study before signing European deal, officials say
Results of highly anticipated Solidarity trial strike blow to hopes for coronavirus treatments
President given experimental treatments for Covid-19 at Walter Reed facility
Both countries have large supplies of generic Covid-19 treatment but distribution to other places has been slow
The only clear winners in this deal are Immunomedics’ shareholders
Offer is worth close to double New Jersey-based Immunomedics’ market value
California biotech company says ‘vast majority’ of existing supplies are in the US
Shares boosted as latest limited trial figures indicate significant cut in fatality rates
Study with 4,566 people found cabotegravir is more effective than current care standard
Investors believe the crisis will ease the political scrutiny that has hung over the US industry
For now, Gilead’s preferred pricing formula reflects the implicit value provided
Health commissioner has been negotiating with US pharma group over Covid-19 drug
US drugmaker criticised over proposed pricing for course of Covid-19 treatment
Move offers hope for patients most severely affected by coronavirus
Governments must accept defeating Covid-19 is a shared interest
US has already been faulted for lottery-like distribution of potential coronavirus drug
Investors have bet on Gilead’s remdesivir as solution to coronavirus crisis
US-led trial shows positive results in hastening recovery time for coronavirus patients
Biotech group’s shares have soared this year on hopes drug could be used to treat coronavirus
International Edition
